Copyright: ©Author(s) 2026.
World J Gastroenterol. Jun 14, 2026; 32(22): 117417
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.117417
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.117417
Figure 1 Histopathological features of patients with combined hepatocellular cholangiocarcinoma.
A: Hematoxylin and eosin staining showing distinct hepatocellular carcinoma-like and cholangiocarcinoma-like regions; B: Immunohistochemical staining for GPC3 confirms the hepatocellular phenotype; C: Immunohistochemical staining for CK19 confirms the cholangiocellular phenotype.
- Citation: Han RY, Wei YK, Liu WN, Wang YM, Song TQ, Tian XD, Xia YR, Chen L, Gong WC. Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy. World J Gastroenterol 2026; 32(22): 117417
- URL: https://www.wjgnet.com/1007-9327/full/v32/i22/117417.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i22.117417